eMed
Employer-focused GLP-1 weight management platform using branded FDA-approved medications with 24/7 clinician support and included lab work.
What we like
What to watch
Full Review
eMed is a well-funded ($200M Series A, $2B+ valuation) telehealth company that has positioned itself primarily as an employer-sponsored GLP-1 weight management platform. Led by former X/Twitter CEO Linda Yaccarino, with Tom Brady as Founding Chief Wellness Officer, the company focuses exclusively on branded FDA-approved GLP-1 medications — no compounded alternatives. eMed claims 90% member adherence (roughly 2x the industry norm) and average weight loss of 21 lbs. The $99/mo program fee includes 24/7 clinician support, annual blood work (32 biomarkers), supervised injections, and insurance prior authorization assistance — but medication costs ($550–$1,300/mo) are separate and set by manufacturers. A CVS Caremark partnership enables employer cost reduction. While the clinical model is strong, eMed's narrow focus (weight loss and urgent care only) and premium total cost make it best suited for patients with employer benefits or insurance coverage.
Last researched: 2026-04-03
Pricing
Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.
| Treatment | Category | Price/mo | Includes | Notes |
|---|---|---|---|---|
| GLP-1 Weight Management Program | Weight Loss / GLP-1 | $649–$1399 | ● Consults● Lab work● Shipping | $99/mo program fee + medication cost ($550–$1,300/mo) Subscription required |